Alcon's Q3 results met consensus with steady 5% revenue growth and 15% core EPS growth, while the tightened full-year guidance suggests management sees stable near-term trends. Watch for the impact of the Neurotech acquisition on the Vision Care retina portfolio and any further tariff developments, as the company expects a net $40M tariff impact for the full year.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $72.46entry
- T+1 · 5d ago −0.87%α −0.52% · $71.83
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alcon reported Q3 2026 net sales of $2.717B, up 5% YoY, and core diluted EPS of $0.91, up 15% YoY, both in line with consensus estimates of $2.74B and $0.89. The company tightened its full-year 2026 outlook, narrowing constant-currency net sales growth to +6%, core operating margin expansion to +100-150 bps, and core EPS growth to +12-14%. The quarter benefited from tariff refunds and strong product launches, while the nine-month IFRS results were impacted by a $505M impairment charge related to the PowerVision program discontinuation.
Key Financial Metrics
Key Facts
- Q3 2026 net sales $2.717B, +5% YoY (in line with $2.74B consensus)
- Q3 2026 core diluted EPS $0.91, +15% YoY (in line with $0.89 consensus)
- Q3 2026 GAAP diluted EPS $0.54, +13% YoY
- Full-year 2026 outlook tightened: cc net sales growth +6%, core operating margin +100-150 bps, core EPS growth +12-14%
- Q3 2026 Vision Care segment contribution +24% YoY, Surgical +7% YoY
- Q3 2026 gross margin 59.7% vs 56.3% YoY; core gross margin 65.7% vs 62.9% YoY
- Nine-month 2026 operating income $684M (-35% YoY) due to $505M PowerVision impairment
- Free cash flow $1.345B for nine months 2026 vs $1.244B prior year
- Acquired Neurotech Pharmaceuticals for $550M closing consideration in October 2026
- $1.0B remaining on $1.5B share repurchase authorization as of Sept 30, 2026
Financial Impact
Q3 2026 net sales $2.717B, core diluted EPS $0.91; full-year guidance tightened to +6% cc sales growth, +12-14% cc core EPS growth
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Surgical | $1.5B | +4.2% |
| Vision Care | $1.2B | +5.8% |
Risk Factors
- U.S. IOL competitive pressures continue, with implantables down 2% in Q3
- Full-year tariff impact of ~$40M net of refunds, with uncertainty on future tariff policy
- PowerVision program discontinuation resulted in $505M impairment; contingent consideration liabilities remain up to $1.0B
- Nine-month GAAP operating income down 35% YoY due to impairment charges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001167379-26-000033 |
| Document: q32026pressrelease.htm | 0001167379-26-000033 |
| Document: form6-kxearningsreleaseand.htm | 0001167379-26-000033 |
| Document: 0001167379-26-000033-index-headers.html | 0001167379-26-000033 |
| Document: 0001167379-26-000033-index.html | 0001167379-26-000033 |
| Document: 0001167379-26-000033.txt | 0001167379-26-000033 |
| Earnings Context (Synthetic; results releases only) | 0001167379-26-000033 |
Track record
5 reports on ALC
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.74% at T+5 after the Jun 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 5/10 Viewing Entry $72.46 Now $73.64 +1.63% settles Feb 9
- Nov 6, 202610d ago Institutional Cluster Mixed 3/10 Entry $74.94 Now $73.64 −1.73% settles Feb 4
- Aug 10, 202614w ago 6-K Bullish 6/10 Entry $75.35 to $77.31 Now $73.64 −2.27% ▲ +2.60% +3.09% vs SPY
- Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.61 to $65.39 Now $73.64 +8.92% ▼ −3.28% −6.90% vs SPY
- Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.80 to $64.87 Now $73.64 +8.61% ▼ −4.32% −8.81% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers